Cargando…
Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease
Background. Parkinson's disease (PD) progressively affects dopaminergic neurotransmission and may affect retinal dopaminergic functions and structures. Objective. This 2-year randomized, open-label, parallel-group, flexible-dose study, NCT00144300, evaluated ophthalmologic safety profiles of im...
Autores principales: | Seiple, William, Jennings, Danna, Rosen, Richard B., Borchert, Leona, Canale, Lee, Fagan, Nora, Gordon, Mark Forrest |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203898/ https://www.ncbi.nlm.nih.gov/pubmed/28078162 http://dx.doi.org/10.1155/2016/8298503 |
Ejemplares similares
-
The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study
por: Wang, Ying, et al.
Publicado: (2014) -
Ophthalmological Features of Parkinson Disease
por: Nowacka, Barbara, et al.
Publicado: (2014) -
Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009) -
Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden
por: Wolfschlag, Mirjam, et al.
Publicado: (2021) -
The Neuro-Ophthalmological Assessment in Parkinson’s Disease
por: Borm, Carlijn D.J.M., et al.
Publicado: (2019)